Third-Generation Cephalosporins
Third-Generation Cephalosporins
Overview
Parenteral Agents:
Cefotaxime & Ceftriaxone: effective for community-acquired pneumonia
Spectrum of Activity
Expanded Gram-Negative Coverage:
Some agents can cross the blood-brain barrier which penetrate body fluids and tissues well.
These cephalosporins exhibit activity against various gram-negative bacteria, including:
Citrobacter
Serratia marcescens
Providencia
Beta-lactamase producing strains of Haemophilus and Neisseria.
HENMPEcKSSS Coverage:
Includes H. influenzae, Enterobacter, Neisseria, Moraxella catarrhalis, Proteus mirabilis, E. coli, K. pneumoniae, Serratia, Salmonella, and Shigella.
Resistance and Excretion
AmpC Beta-Lactamase Hydrolysis:
Susceptibility is compromised for Enterobacter as they can hydrolyze these agents.
Renal Excretion:
All are excreted through the kidney except ceftriaxone (which is mainly via the bile as mixed)
Antipseudomonal Cephalosporins
Cefoperazone, Cefotaxime, Ceftazidime, Ceftriaxone, Moxalactam
Specific Dosages and Use Cases
Ceftriaxone:
2g every 12 hours for meningitis treatment, 2g once daily for endocarditis.
Excellent CNS penetration allows effective treatment of central nervous system infections.
Broad activity including treatment for pneumonia, meningitis, pyelonephritis, and gonorrhea
Has primarily mixed clearance (renal and biliary) with a half-life of approximately 6 hours.
Recommended regimen along with Azithromycin for gonococcal infections via the intramuscular (IM) route.
The drug is considered the new drug of choice (DOC) for typhoid fever.
Cefotaxime:
Similar in efficacy to Ceftriaxone but primarily renally cleared with a half-life of 1 hour.
Cefixime (PO):
200 mg twice a day or 400 mg once a day for urinary tract infections
However, no longer recommended for uncomplicated gonococcal urethritis and cervicitis.
Noted to have lesser activity against pneumococci and poor activity against Staphylococcus aureus.
Ceftazidime:
Poor Gram-Positive Activity:
Limited efficacy against gram-positive organisms with absence of activity against Staphylococcus aureus.
It is the only third-generation cephalosporin with activity against Pseudomonas aeruginosa.
Ceftibuten:
400 mg once a day; noted to have lesser activity against pneumococci and poor activity against Staphylococcus aureus.
Cefpodoxime proxetil or Cefditoren pivoxil:
200-400 mg twice a day, with limited usage against certain organisms.